Avcn583601 (3% cannabidiol cream) (DrugBank: Cannabidiol)
19 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
6 | Parkinson disease | 0 |
8 | Huntington disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
36 | Epidermolysis bullosa | 1 |
46 | Malignant rheumatoid arthritis | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
140 | Dorabe syndrome | 0 |
144 | Lennox-Gastaut syndrome | 0 |
145 | West syndrome | 0 |
156 | Rett syndrome | 0 |
157 | Sturge-Weber syndrome | 0 |
158 | Tuberous sclerosis | 0 |
193 | Prader-Willi syndrome | 0 |
206 | Fragile X syndrome | 0 |
226 | Interstitial cystitis with Hunners ulcer | 0 |
271 | Ankylosing spondylitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04613102 (ClinicalTrials.gov) | August 1, 2020 | 27/10/2020 | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | Epidermolysis Bullosa;Pain;Itch | Drug: AVCN583601 (3% Cannabidiol cream) | Elena Pope | Avicanna Inc | Withdrawn | 4 Years | 50 Years | All | 0 | Phase 2;Phase 3 | Canada |